ArticleNeurology and therapy2026
Clinical Characteristics, Treatment Patterns, and Drug-Resistant Epilepsy Among Emirati Adults with Epilepsy.
Article in Neurology and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionDetailed clinical descriptions of treated adult epilepsy in the Arab region remain scarce. We examined epilepsy type, antiseizure medication (ASM) use, comorbidities, and drug-resistant epilepsy (DRE) in Emirati adults with epilepsy in the United Arab Emirates (UAE).
methodsWe conducted a retrospective cohort study of Emirati adults aged 18-65 years attending neurology clinics at a tertiary center in Al Ain between January 2019 and January 2024. Patients were screened from neurology clinic visits, and those with at least one G40.909 coded encounter underwent chart review. Epilepsy type was classified using 2017 International League Against Epilepsy frameworks. DRE was defined as failure of at least two appropriately chosen and tolerated ASMs. Clinical and treatment data were extracted from electronic medical records.
resultsThe cohort included 204 adults [median age 34 years (26.0-44.2); 55.9% male]. Epilepsy type was specified in 178/204 patients; among whom generalized epilepsy was more common than focal epilepsy (66.9% vs. 33.1%). Monotherapy was the most common recorded treatment pattern (66.7%), and levetiracetam was the most frequently prescribed ASM (50.0%). Dyslipidemia (38.7%) and type 2 diabetes mellitus (12.7%) were the most common comorbidities. DRE was identified in 36/150 patients (24.0%) with available prior ASM failure data and in 36/204 patients (17.6%) in the full cohort.
conclusionsThis study adds data on adult epilepsy from an underrepresented Emirati population. Most patients were treated with ASM monotherapy, and levetiracetam was the most commonly prescribed drug. Cardiometabolic comorbidities were common. DRE was seen in nearly one in four patients with available prior ASM failure data, while the lower estimate in the full cohort was at least one in six patients. These findings highlight the need for better clinical documentation and for larger multicenter studies in the UAE and the wider region.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.